Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty - The EMPAR study

被引:118
作者
Cairns, JA
Gill, J
Morton, B
Roberts, R
Gent, M
Hirsh, J
Holder, D
Finnie, K
Marquis, JF
Naqvi, S
Cohen, E
机构
[1] MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON, ON L8N 3Z5, CANADA
[2] UNIV OTTAWA, DEPT MED, OTTAWA, ON, CANADA
[3] UNIV WESTERN ONTARIO, LONDON, ON N6A 3K7, CANADA
[4] UNIV TORONTO, TORONTO, ON M5S 1A1, CANADA
关键词
angioplasty; restenosis; fish oils; heparin; coronary disease;
D O I
10.1161/01.CIR.94.7.1553
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Percutaneous transluminal coronary angioplasty (PTCA) is complicated by restenosis within 6 months in >40% of patients. Theoretical, animal experimental, and human epidemiological and clinical trial findings have suggested that fish oils (n-3) might reduce restenosis. Low-molecular-weight heparin (LMWH) has reduced cellular proliferation and restenosis in several experimental systems. Methods and Results We randomized 814 patients to fish oils (5.4 g n-3 fatty acids) or placebo a median of 6 days before PTCA and continued for 18 weeks. At the time of sheath removal, 653 patients with at least one successfully dilated lesion were randomized to LMWH (30 mg SC BID) or control for 6 weeks in a 2 x 2 factorial design. Follow-up with quantitative coronary angiography (QCA; target, 18 weeks) was interpretable on 96% of these patients. Restenosis rates per patient were for n-3, 46.5%; placebo, 44.7%; LMWH, 45.8%; and control, 45.4%. Restenosis rates per lesion were for n-3, 39.7%; placebo, 38.7%; LMWH, 38%; and control, 40.4%. At follow-up QCA, mean minimal lumen diameters were (mm) for n-3, 1.12; placebo, 1.10; LMWH, 1.12; and control, 1.10. Fifteen percent of patients permanently discontinued n-3/placebo before study completion, and 21% of patients discontinued LMWH early. There were no significant differences in the occurrences of ischemic events. Bleeding was more common with LMWH, usually was mild, and led to early discontinuation of study medication in only 0.9% of patients. Gastrointestinal side effects were more common in patients receiving n-3 than placebo. Conclusions There is no evidence for a clinically important reduction of PTCA restenosis in this trial by either n-3 or LMWH. Evaluation of the results for n-3 in the context of previously published data on the reduction of PTCA restenosis indicates that n-3 is not efficacious and that further trials are unwarranted.
引用
收藏
页码:1553 / 1560
页数:8
相关论文
共 40 条
  • [11] DEVRIES CJ, 1991, EUR HEART J, V12, P386
  • [12] EFFECT OF 18-HOUR TO 24-HOUR HEPARIN ADMINISTRATION FOR PREVENTION OF RESTENOSIS AFTER UNCOMPLICATED CORONARY ANGIOPLASTY
    ELLIS, SG
    ROUBIN, GS
    WILENTZ, J
    DOUGLAS, JS
    KING, SB
    [J]. AMERICAN HEART JOURNAL, 1989, 117 (04) : 777 - 782
  • [13] LOW-MOLECULAR-WEIGHT HEPARIN IN PREVENTION OF RESTENOSIS AFTER ANGIOPLASTY - RESULTS OF ENOXAPARIN RESTENOSIS (ERA) TRIAL
    FAXON, DP
    SPIRO, TE
    MINOR, S
    COTE, G
    DOUGLAS, J
    GOTTLIEB, R
    CALIFF, R
    DOROSTI, K
    TOPOL, E
    GORDON, JB
    OHMEN, M
    RAIZNER, A
    PAR, T
    CURRIER, J
    HANKIN, B
    [J]. CIRCULATION, 1994, 90 (02) : 908 - 914
  • [14] A RANDOMIZED COMPARISON OF CORONARY-STENT PLACEMENT AND BALLOON ANGIOPLASTY IN THE TREATMENT OF CORONARY-ARTERY DISEASE
    FISCHMAN, DL
    LEON, MB
    BAIM, DS
    SCHATZ, RA
    SAVAGE, MP
    PENN, I
    DETRE, K
    VELTRI, L
    RICCI, D
    NOBUYOSHI, M
    CLEMAN, M
    HEUSER, R
    ALMOND, D
    TEIRSTEIN, PS
    FISH, RD
    COLOMBO, A
    BRINKER, J
    MOSES, J
    SHAKNOVICH, A
    HIRSHFELD, J
    BAILEY, S
    ELLIS, S
    RAKE, R
    GOLDBERG, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (08) : 496 - 501
  • [15] FAILURE OF HEPARIN TO INHIBIT INTIMAL HYPERPLASIA IN INJURED BABOON ARTERIES - THE ROLE OF HEPARIN-SENSITIVE AND HEPARIN-INSENSITIVE PATHWAYS IN THE STIMULATION OF SMOOTH-MUSCLE CELL-MIGRATION AND PROLIFERATION
    GEARY, RL
    KOYAMA, N
    WANG, TW
    VERGEL, S
    CLOWES, AW
    [J]. CIRCULATION, 1995, 91 (12) : 2972 - 2981
  • [16] ASSESSMENT OF THE THERAPEUTIC USE OF N-3 FATTY-ACIDS IN VASCULAR-DISEASE AND THROMBOSIS
    GOODNIGHT, SH
    CAIRNS, JA
    FISHER, M
    FITZGERALD, GA
    [J]. CHEST, 1992, 102 (04) : S374 - S384
  • [17] DETERMINANTS OF RESTENOSIS AND LACK OF EFFECT OF DIETARY SUPPLEMENTATION WITH EICOSAPENTAENOIC ACID ON THE INCIDENCE OF CORONARY-ARTERY RESTENOSIS AFTER ANGIOPLASTY
    GRIGG, LE
    KAY, TWH
    VALENTINE, PA
    LARKINS, R
    FLOWER, DJ
    MANOLAS, EG
    ODEA, K
    SINCLAIR, AJ
    HOPPER, JL
    HUNT, D
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1989, 13 (03) : 665 - 672
  • [18] LOW-MOLECULAR-WEIGHT HEPARIN VERSUS REGULAR HEPARIN OR ASPIRIN IN THE TREATMENT OF UNSTABLE ANGINA AND SILENT ISCHEMIA
    GURFINKEL, EP
    MANOS, EJ
    MEJAIL, RI
    CERDA, MA
    DURONTO, EA
    GARCIA, CN
    DAROCA, AM
    MAUTNER, B
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 26 (02) : 313 - 318
  • [19] INHIBITION OF RAT ARTERIAL SMOOTH-MUSCLE CELL-PROLIFERATION BY HEPARIN - INVIVO STUDIES WITH ANTI-COAGULANT AND NON-ANTICOAGULANT HEPARIN
    GUYTON, JR
    ROSENBERG, RD
    CLOWES, AW
    KARNOVSKY, MJ
    [J]. CIRCULATION RESEARCH, 1980, 46 (05) : 625 - 634
  • [20] A METAANALYSIS OF RANDOMIZED TRIALS OF CALCIUM-ANTAGONISTS TO REDUCE RESTENOSIS AFTER CORONARY ANGIOPLASTY
    HILLEGASS, WB
    OHMAN, EM
    LEIMBERGER, JD
    CALIFF, RM
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1994, 73 (12) : 835 - 839